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A Proposal Concept of a Polygene
Network in Systemic Vasculitis: Les-
sons from MRL Mouse Models
Masato Nose1
ABSTRACT
In addition to the studies of cellular and molecular events in the pathogenesis of systemic vasculitis, a genome
analysis of mouse models may shed some light on the complex clinicopathological manifestations of systemic
vasculitis. In the study of susceptibility loci to vasculitis in MRL mouse models, we learned that systemic vascu-
litis developed in a cumulative effect of multiple gene loci, each of which by itself did not have a significant ef-
fect to induce the related phenotype, thus indicating a polygenic system. The mice developed vasculitis in an
additive manner of multiple genes with a hierarchical effect. Some of the susceptibility loci seemed to be com-
mon to those in other collagen diseases as well. Moreover, the loci controlling tissue specificity of vasculitis
were present. One of the positional candidate genes for vasculitis showed an allelic polymorphism in the coding
region, thus possibly causing a qualitative difference in its function. As a result, a particular combination of poly-
genes with such an allelic polymorphism may thus play a critical role in leading the cascade reaction to develop
vasculitis, and also a regular variation of systemic vasculitis. This is designated as the polygene network in sys-
temic vasculitis.
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INTRODUCTION
Systemic vasculitis is involved in collagen disease,
which was first proposed by P. Klemperer in 1945, by
showing the characteristic feature of fibrinoid degen-
eration of connective tissues involving blood vessels.1
At present, this disease category has been revised as
a syndrome overlapping connective tissue diseases,
rheumatic diseases and autoimmune or immunologi-
cal disorders. Systemic vasculitis in collagen disease
has been divided into primary and secondary forms
based on the clinical and pathological findings.2-4 The
former consists of specific clinical entities in which
the pathology involves primarily the blood vessels.
This group has been called vasculitis syndromes as
represented by polyarteritis nodosa, microscopic
polyangiitis, giant cell arteritis, Takayasu arteritis,
Wegener’s granulomatosis, allergic granulomatous
angiitis, Kawasaki disease, etc. On the other hand,
the latter has been categorized as vasculitis which de-
veloped as a complication of other collagen diseases,
such as systemic erythematosus, rheumatoid arthritis
and Sjogren’s syndrome, systemic sclerosis, inflam-
matory myopathies, etc. This complication has been
understood to be a manifestation of advanced dis-
ease, possibly caused by the expansion of autoanti-
bodies, immune complexes and or abnormal T cell
subsets. However, this categorization is complicated
when considering the many cases of primary sys-
temic vasculitis overlapping with other collagen dis-
eases or with atypical collagen disease not satisfied
with the criteria of each disease.3 Moreover, several
similar pathological manifestations of systemic vascu-
litis between the primary and secondary forms have
been reported as represented by fibrinoid degenera-
tion and cellular inflammatory lesions of arterial me-
dia.5 These manifestations may suggest the existence
of common biological rules for systemic vasculitis in
collagen disease beyond the primary and secondary
forms.
The MRLMpJ- lprlpr (MRLlpr) strain of mice
originally established by E. Murphy in 1978,6 as well
Allergology International. 2007;56:79-86
REVIEW ARTICLE
1Department of Pathogenomics, Ehime University Graduate
School of Medicine, Ehime, Japan.
Correspondence: Masato Nose, Department of Pathogenomics,
Ehime University Graduate School of Medicine, Shitsugawa, To-
on City, Ehime 791−0295, Japan.
Email: masanose@m.ehime―u.ac.jp
Received 22 January 2007.
2007 Japanese Society of Allergology
DOI: 10.2332allergolint.R-04-140
Nose M
80 Allergology International Vol 56, No2, 2007 www.jsaweb.jp
Fig. 1 Representative histopathological manifestations of systemic vasculitis in MRL/lpr mice 
(A; arcuate artery in the kidney, B; main branch of the aorta, C; artery in the lower extremity), com
monly showing granulomatous arteritis characteristic of the accumulation of lymphocytes and 
macrophages in the perivascular regions, folowed by the destruction of the adventitia and tunica 
media, and then the intimal thickening.
as (NZB x NZW) F1 and BXSB mice, have been used
to study systemic lupus erythematosus.7,8 This strain
is designated as a murine lupus model, since MRL
lpr mice develop lethal glomerulonephritis associated
with severe immune complex deposition in glomeruli
and increased autoantibodies involving anti-ds-DNA
and Sm antibodies. However, this strain also develops
systemic vasculitis, polyarthritis and sialoadenitis,
thus resembling polyarteritis nodosa, rheumatoid ar-
thritis and Sjögren’s syndrome, respectively, and
shows the high titers of IgG rheumatoid factor and
anti-MPO antibodies.8,9 These findings suggest that
this stain should be used as a collagen disease model.
Therefore, the systemic vasculitis observed in these
mice might be a secondary form associated with
other types of collagen disease.
In this paper, we will review the study of vasculitis
from a genetic aspect. With our study of MRL mice,
we will conclude that systemic vasculitis in these
mice can develop independently from other types of
collagen disease, and finally that this mechanism of
action is under the control of a polygene network.
SYSTEMIC VASCULITIS IN MRL MICE
MRLlpr mice develop systemic vasculitis associated
with the single mutation gene, lpr (lymphoprolifera-
tion),1 which encodes the deletion mutant of Fas, re-
sulting in the immunological disturbance of Fas-
mediated apoptosis.10 At 16 weeks old, more than 80%
of the mice spontaneously develop vasculitis in the
kidneys, mainly in the arcuate and interlobular arter-
ies (as shown in Fig. 1). Vasculitis in main branches
of the aorta, and arteries in the extremities, pancreas
and salivary glands also develops to a lesser extent.
Similar lesions can be observed in the MRL strain of
mice congenic with another single mutation gene, gld
(generalized lymphoproliferative disease), MRLMpTn-
gldgld (MRLgld).11,12 The gld mutation was origi-
nally derived from C3HHeJ mice, but in this stain
vasculitis was not observed.13 The relationship of the
lpr and gld genes was suggested to be that of receptor
and ligand in a study of bone marrow chimera.14 Fi-
nally the gld gene was clarified to be the point muta-
tion of Fas ligand (FasL) that induces a loss of func-
tion of the FasFasL interaction.15
The common histopathological feature of vasculitis
in MRLlpr mice is granulomatous arteritis.16 In our
previous study,17 the lesion seemed to be initiated by
the accumulation of CD4+T cells in the perivascular
regions, followed by macrophages positive for Mac-2
(galectin-3) forming a granulomatous lesion involving
the adventitia and tunica media. Then, the lesion ex-
tended to form fibrinoid necrotic lesions of the media
associated with the influx of plasma components from
the vascular lumen. In MRLgld mice, though not in
MRLlpr mice, a large proportion of cells in the vas-
culitic lesions expressed Fas, mainly including lym-
phoid cells and macrophages.17 A single administra-
tion of anti-Fas monoclonal antibodies (RA-8 clone)
into MRLgld mice ameliorated vasculitis.18 These
findings indicate that an inefficient interaction be-
tween Fas and FasL and a consequent deficit in Fas-
mediated apoptosis are critical for the development of
vasculitis in the MRL strain of mice.
The reconstruction of the vascular lesions in
[MRLgld- > MRL+] mice was successful carried
out in bone marrow irradiation chimeras.19 Several
trials of cell transfer in [MRLlpr- > MRL+] mice
had failed to develop both lymphoproliferation and
vasculitis because of the development of runt-like dis-
ease.14 This result may be explained by the effect of
FasL produced in donor cells of MRLlpr mice, which
induces apoptosis of Fas expressing cells in MRL+
recipients via FasFasL interaction. In the [MRLgld-
> MRL+] mice, vascular lesions and also glomerular
lesions were characteristic of endocapillary prolifera-
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tive glomerulonephritis associated with immune com-
plex deposits which were almost the same as those in
MRLlpr mice. Interestingly, vasculitis did not de-
velop when the same H-2k strain of mice, C3HHeJ
were used as the recipients although they did de-
velop glomerulonephritis as same as that in [MRL
gld- > MRL+] mice. Between both bone marrow chi-
meras, there was no difference in the higher serum
levels of IgG and immune complexes. This dissocia-
tion might indicate a different cellular mechanism for
vasculitis from that for glomerulonephritis.
According to these histopathological findings,
macrophages seem to be critical effector cells for the
destruction of external elastic lamina of the arterial le-
sions. In previous studies,20 macrophages in MRLlpr
mice were remarkably activated, characterized by
higher ingestion, but lower digestion in comparison
with those in MRL+ mice, and released high concen-
trations of oxygen radicals when stimulated with zy-
mosan. Yui et al.21 reported that the serum level of M-
CSF in MRLlpr mice was increased before the onset
of diseases. The treatment of spleen macrophages of
MRL+ mice with M-CSF induced high expression of
Mac-2 positive cells, coincident with Fas.17 The con-
tinuous infusion of M-CSF into the subcutis of an
MRL+ mice in vivo causes the development of
granulomatous lesions along with the accumulation
of Mac-2 positive cells.17 MCP-1 is also a critical fac-
tor for the development of vasculitis. MCP-1 antago-
nist significantly inhibited the granulomatous lesions
in MRLlpr mice.22 Recently, it has become clear that
MIF deficiency in MRLlpr mice reduced MCP-1 ex-
pression, but it was not associated with a reduction in
IFN-γ expression in the kidneys.23 These findings
may indicate that macrophage recruitment to vascu-
lar lesions is one of the important steps in the cas-
cade reaction to complete the development of granu-
lomatous vasculitis.
A SINGLE GENE MUTATION BY ITSELF
CANNOT CAUSE VASCULITIS
Since the MRLlpr strain of mice was established,
molecular and cellular events associated with vasculi-
tis have been pointed out to elucidate the role of the
mutant gene, lpr in the developmental mechanisms of
autoimmune diseases.8 However, fundamental evi-
dence shows that MRLlpr mice require not only the
lpr gene but also an MRL genetic background for the
development of autoimmune diseases involving sys-
temic vasculitis. Namely, other lpr congenic strains of
mice, such as C3HHeJ-lprlpr (C3Hlpr) and C57
BL6-lprlpr (B6lpr), showed no significant disease
phenotypes except lymphoproliferation, such as vas-
culitis, glomerulonephritis, sialoadenitis and arthri-
tis.11 However, these stains showed autoimmune phe-
notypes characteristic of the higher serum levels of
autoantibodies, rheumatoid factors and immune com-
plexes to a lesser extent to those in MRLlpr mice.24
In vascular lesions of C3Hlpr and B6lpr mice, only
the accumulation of lymphocytes into the perivascu-
lar regions was observed, but there was no destruc-
tion of the vascular wall and no granuloma forma-
tion.13 Hence, MRLlpr mice also teach us that there
is a great discrepancy between autoimmune traits
and the disease phenotypes.
In recent studies of several autoimmune disease
models using gene targeting, a targeting gene by it-
self might be seemingly related to disease pheno-
types. However, some of the disease phenotypes are
significantly controlled by the host’s background
genes. For example, FcrRIIB gene targeting develops
vasculitis and glomerulonephritis in a B6 strain of
mice, but these disease phenotypes were remarkably
reduced in a BALBc background.25 Another exam-
ple shows that a single gene targeting develops a dif-
ferent disease phenotype in the face of a different ge-
netic background. In targeting of the IL-1 receptor an-
tagonist gene, B6 mice develop aortitis, but BALBc
mice develop arthritis.26,27 PD-1 gene targeting in-
duces glomerulonephritis and arthritis in a B6 back-
ground, but induces dilated cardiomyopathy in a
BALBc strain of mice.28,29 Looking back at MRLlpr
mice, the mutant gene, lpr, may be a landmark giving
us a concept that a single gene by itself cannot cause
autoimmune diseases and disease phenotypes are pri-
marily dependent on the host’s background genes.
GENETIC SEGREGATION OF VASCULITIS
FROM OTHER COLLAGEN DISEASES
To develop vasculitis, the background genes of MRL
mice are required in addition to the lpr or gld gene.
Do these genes for vasculitis in MRLlpr mice share
those for glomerulonephritis and other collagen dis-
eases? This aspect is important in order to under-
stand the genetic basis of human renovascular dis-
eases and also to validate the categorization of secon-
dary systemic vasculitis associated with collagen dis-
eases. In the pathological studies of MRLlpr x recip-
rocal (MRLlpr x B6lpr) F1 mice, vasculitis and
glomerulonephritis were clearly dissociated. 13
Among the backcross generation, some mice devel-
oped only vasculitis or glomerulonephritis, while oth-
ers developed both or none. Similar findings were ob-
served in MRLlpr x (MRLlpr x C3Hlpr) F1 mice,
where each of the lesion was clearly dissociated from
arthritis andor sialoadenitis (Fig. 2). The genetic dis-
sociation of vasculitis from glomerulonephritis was
more clearly demonstrated by the establishment of
the McH5-lprlpr (McH5lpr) stain of mice, which is
a vasculitis-congenic strain derived from MRLlpr
and C3Hlpr crosses.30 More than 90% of McH5lpr
mice developed vasculitis, but less than 10% devel-
oped glomerulonephritis at 16 to 20 weeks of age in
contrast to MRLlpr mice (vasculitis; 86%, glomeru-
lonephritis; 98%).
Such a genetic segregation of the disease pheno-
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Fig. 2 Genetic dissociation of each lesion of colagen disease in MRL/lpr x 
(MRL/lpr x C3H/lpr) F1 mice. Among them, mice developing only vasculitis, 
glomerulonephritis, arthritis or sialoadenitis and also mice with several combi
nations between them were observed.
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types might also give us a novel aspect in the study of
the mechanisms of vasculitis. In a previous study of
vasculitis in MRLlpr mice, anti-DNA and anti-
myeloperoxidase (MPO) antibodies have been sug-
gested as being involved in the development of vascu-
litis.9,31 However, in McH5lpr mice, the serum levels
of anti-DNA and anti-MPO antibodies were almost
normal. These findings may teach us that several se-
rological traits seemingly associated with disease
phenotypes in autoimmune diseases might in fact be
bystanders, thus reflecting neither the results nor the
causes of diseases.
VASCULITIS DEVELOPS WITH AN ADDITIVE
MANNER OF MULTIPLE GENES
In general, to clarify background genes for disease
phenotypes on the whole genome of a mouse model,
chromosomal mapping of susceptibility loci to the dis-
ease phenotype is useful, which is based on the prin-
ciple of chromosomal recombination of the germ line
during meiosis. That is, an intercross or backcross
generation between the disease model strain and
non-disease strain is prepared, and then polymorphic
gene markers derived from the progenitors closely
associated with a disease phenotype can be identified
statistically.32 At present, more than 6,000 of micro-
satellite markers on mouse chromosomes have been
identified. Polymorphic markers are available to use
as markers for disease susceptibility loci, and many
single nucleotide polymorphism (SNPs) markers in
several mouse strains also have became available
(http:www.informatics.jax.org). These markers
are dependent on the law of segregation of Mende-
lian inheritance even if disease phenotypes might not
be. By applying this principle, many susceptibility loci
to autoimmune and disease phenotypes have been in-
vestigated in murine lupus models,33 but susceptibil-
ity loci to vasculitis have so far hardly been investi-
gated.
In the studies of the susceptibility loci to collagen
diseases using MRLlpr x (MRLlpr x C3Hlpr) F1
and (MRLlpr x C3Hlpr) F2 mice (Table 1), several
genetic roles of vasculitis in this strain were clarified.
Three susceptibility loci to vasculitis in the kidneys
(Arvm1, Arvm2 and D3Mit42) have an additive man-
ner in genetic inheritance (Fig. 3).34 That is, each of
three loci with susceptible genotypes showed a low
incidence of vasculitis (40 to 60%), but the combina-
tion of all of these loci together induced a higher inci-
dence (90%). This may indicate the existence of an
additive or cumulative effect for the development of
vasculitis among these three susceptibility loci. More-
over, the combination of Arvm1 and Arvm2 with sus-
ceptible genotypes showed a 70% incidence of vasculi-
tis; however in another combination of Arvm1 and D3
Mit42 or Arvm2 and D3Mit42 there was no additive
effect in the development of vasculitis. These findings
indicate a hierarchical effect among these susceptibil-
ity loci. In addition, McH5lpr mice had the suscepti-
ble genotypes in all of these loci.
TISSUE SPECIFIC SUSCEPTIBILITY LOCI
TO VASCULITIS
Vasculitis in MRLlpr mice is systemic involving the
renal arteries, main branches of the aorta and arteries
in the extremities (Fig. 1). Chromosomal mapping of
vasculitis in each artery showed a different position
on each of the chromosomes each other (Table 1),
namely, vasculitic lesions in different tissues are un-
der the control of different susceptibility loci. Suscep-
tibility loci to vasculitis in the extremities (Aevm1 and
Aevm2) were located on chromosome 8 and 5, re-
Polygene Network in Vasculitis
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Fig. 3 An additive and hierarchical efect among the sus
ceptibility loci to vasculitis in the kidneys. Combination of the 
loci with susceptible genotypes (Arvm1; MRL/MRL, Arvm2; 
MRL/MRL, D3Mit42; MRL/C3H) regulates the incidence of 
vasculitis (%).
Arvm1 MRL/MRL
D3Mit42 MRL/C3HArvm2 MRL/MRL
9/15
60%
36/40
90%
12/25
48%4/7
57%
7/13
54%
9/16
56%
26/33
79%
Table 1 The susceptibility loci to vasculitis and other colagen diseases determined by using MRL/lpr x (MRL/lpr x C3H/lpr) F1 
and (MRL/lpr x C3H/lpr) F2 mice.
RefsPositionChrMGI: IDNameSymbolLesions
34 19.8 cM 4MGI: 2149546autoimmune renal vasculitis in MRL mice 1Arvm1Vasculitis
34 58.0 cM 4MGI: 2149547autoimmune renal vasculitis in MRL mice 2Arvm2
3455―61 cM 3autoimmune renal vasculitis in MRL mice 3Arvm3
35 13.3 cM 4MGI: 2680905autoimmune aortitis in MRL mice 1Aaom1
35 33.0 cM 8MGI: 2680906autoimmune extremity vasculities in MRL mice 1Aevm1
35 65.0 cM 5MGI: 2680907autoimmune extremity vasculities in MRL mice 1Aevm2
36 22.0 cM 4MGI: 3582415autoimmune glomerulonephritis in MRL mice 1Agnm1Glomerulonephritis
36 53.0 cM 4MGI: 3582416autoimmune glomerulonephritis in MRL mice 2Agnm2
36 56.0 cM 5MGI: 3582417autoimmune glomerulonephritis in MRL mice 3Agnm3
40 18.0 cM15MGI: 2387302progression of autoimmune arthritis in MRL mice 1Paam1Arthritis
40 49.0 cM19MGI: 2387303progression of autoimmune arthritis in MRL mice 2Paan2
40 24.5 cM 7progression of autoimmune arthritis in MRL mice 3Paam3
40 45.0 cM 2progression of autoimmune arthritis in MRL mice 4Paam4
40100.0 cM 1progression of autoimmune arthritis in MRL mice 5Paam5
41 40.0 cM10MGI: 3588383arthropathy in MRL and DBA/1 mice 1Artmd1 
(Amd1)
41 29.5 cM 3MGI: 3588384arthropathy in MRL and DBA/1 mice 2Artmd2 
(Amd2)
42 39.0 cM10MGI: 2150642autoimmune sialoadenitis in MRL mice 1Asm1Sialoadenitis
42 51.0 cM 4MGI: 2150643autoimmune sialoadenitis in MRL mice 2Asm2
42 65.0 cM 1autoimmune sialoadenitis in MRL mice 3Asm3
42 20.0 cM18autoimmune sialoadenitis in MRL mice 4Asm4
MGI: ID are available in htp:/www.informatics.jax.org/.
spectively, but both of which were not shared with
those in the renal arteries (Arvm1 Arvm2 and D3Mit
42) or main branches of the aorta (Aaom1，D5Mit
23).35 Aaom1 was located on chromosome 4, interest-
ingly close to Arvm1, thus indicating a high linkage
value between these two loci.
The genome of the MRL strain of mice is a mosaic
of the genomes of the LGJ, AKRJ, C3HDi and C57
BL6J strains.6 Aaom1 in the MRL strain came from
the AKRJ or LGJ strain, and Aevm1 and Aevm2 loci
originated from the AKRJ and LGJ strains, respec-
tively.35 These findings were similar to those for the
two susceptibility alleles to vasculitis in the kidneys,
Arvm1 and Arvm2 in the MRL strain which originate
from the LGJ and AKRJ strains, respectively.34
Such different allelic origins of the susceptibility loci
in the MRL strain may explain why MRL mice seem
to develop vasculitis over almost their entire bodies,
namely, it may result from the cumulative effect of
the susceptible alleles derived from AKRJ and LGJ
strains, each of which corresponds to vasculitis in a
specific tissue. From these findings we can speculate
that the variations in the tissue- or organ- distribu-
tion of vasculitis in human in vasculitis syndromes
and other collagen diseases might, at least partially,
be caused by a combination of susceptible alleles re-
sulting from genome crosses.
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Fig. 4 Genetic polymorphism of Cd72 between the MRL/lpr and C3H/lpr strains 
at the intron 7/exon 8 junction. The change of ag-＞ ct at the splice site in the 
MRL/lpr strain leads a 21 bp deletion of the exon 8, resulting a deletion of 7 amino 
acids in the extacelular domain of CD72.
Exon/intron
structure
intron 7
C3H/lpr (CD72b)
MRL/lpr (CD72c) ― ― ― ― ― ― c t  ― t c t  ―  c a ― ― ― t  ― ― ― ― ― ― ― ― ― ― C T C A T A T
exon 8
intron 7 splice site
splice site
exon 8
CCGACATt t c a c c ag GCAGGAC C TT GAC T GT C AA AC
Fig. 5 A proposal concept of a polygene network in vasculitis. Each polygene regu
lating the susceptibility to vasculitis (gene 1 to 6) may have quantitatively a diferent 
function in the cascade reaction to the development of vasculitis, dependent on its 
genotype (A or B). An environmental signaling stimulates genes 1A and 1B equaly to 
lead the second step of the expression of gene 2A and 2B and genes 3A and 3B. How
ever, gene 3B cannot be expressed higher or lead the stronger efect to inhibit the reac
tion of gene 2 to gene 4 than gene 3A. On the other hand, gene 5 existing in the down 
stream of gene 2 and accelerating the step of gene 4 to gene 6, can act stronger with 
the A genotype. Finaly, gene 6 is highly expressed for the development of vasculitis, 
but which is not required to be polymorphic.
polygenes : 1 6 (polymorphism: A, B)
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inhibit
accelerate
diseased
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Cd72 AS A POSITIONAL CANDIDATE GENE
FOR VASCULITIS AND GLOMERULONE-
PHRITIS
Vasculitis in MRLlpr mice was genetically segre-
gated from glomerulonephritis as mentioned above.
However, map positions of two of three susceptibility
loci to vasculitis on chromosome 4, Arvm1 and Arvm
2,36 were much closer to two of those to glomeru-
lonephritis, Agnm1 and Agnm2, respectively. This
means that these loci may be common to both dis-
ease phenotypes or have a high linkage value.
A candidate gene for Arvm1 and Agnm1 was deter-
mined to be Cd72 based on the result that there was
a severe polymorphism on the coding region between
the MRL and C3H strains, namely Cd72 cDNA in the
MRL strain had a 3 bp insertion between positions
950 and 951 in exon 7, and a 21 bp deletion from 966
to 986 at the intron 7exon 8 junction (Fig. 4), thus
resulting from alternative splicing.34 This indicates
that the MRL allele of CD72 was consistent with a
CD72c haplotype, while that of C3H was a CD72b
haplotype.37 Moreover, the MRL strain had 13 amino
acid substitutions consisting of acidic, basic and neu-
tral amino acids compared with the C3H strain.
CD72 is a negative regulator of B-cell activation,
acting through its immunoreceptor tyrosine-based in-
hibitory motif (ITIM) in exon 1.38 Although the ITIM
Polygene Network in Vasculitis
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itself was well conserved in the MRL allele, the allelic
polymorphism between the MRL and C3H strains in-
cluding a 21 bp deletion at the intron 7exon 8 junc-
tion and 13 amino acid substitutions may be sufficient
to induce the functional difference between the CD72
molecules in the MRL and C3H strains. The CD72c
allele is likely to contribute to the development of vas-
culitis associated with the other two susceptibility loci
via a limited antibody production. This theory is
based on the fact that a vasculitis-prone strain of
McH5lpr mice has decreased anti-DNA and anti-
myeloperoxidase antibodies, but not rheumatoid fac-
tors and circulating immune complexes, compared to
the MRLlpr strain.30 Actually, this strain had the
CD72c allele. In addition, the other lupus-prone
strains of mice such as NZB, NZW and BXSB have
the same CD72b allele as C3HHeJ, thus suggesting
that the MRL allele CD72c might contribute uniquely
to the development of vasculitis.34
POLYGENE NETWORK OF VASCULITIS
In general, the genetic basis of diseases is divided
into two major groups. One is the result of a gene de-
fect or a mutation which induces common disease
phenotypes not influenced by the host’s genetic back-
ground. The other one is that disease develops as the
result of a cumulative effect of multiple genes, each of
which by itself cannot induce the particular pheno-
type significantly. The former encodes almost a quali-
tative phenotype, while the latter encodes a quantita-
tive phenotype, which is not dependent on a Mende-
lian inheritance. This system was classified as “poly-
genic inheritance” by K. Mather in 1949.39 Each poly-
gene may distribute into the population of a species
through an evolution process, influenced by a genetic
drift, taking advantage of escaping from natural selec-
tion. Vasculitis is under the control of polygenes ac-
cording to the law proposed by Mather, which in-
volves polymorphic genes and also a mutant gene en-
coding lymphoproliferation in the case of MRLlpr
mice. Some of the polygenes, such as Cd72, may also
be common in other collagen diseases.
Polygenes may quantitatively regulate the cascade
reactions extending to the development of vasculitis
and other collagen disease with a regular variation of
the pathologic phenotypes based on their combina-
tions. In the cascade reaction, as shown in Figure 5,
some polymorphic gene such as Cd72MRL might be
less suppressive than Cd72C3H, and other ones with
MRL alleles might be more accelerative, leading to
excessive production of effector molecules or cells
having them. In this hypothesis, effectors themselves
are not required to be polymorphic for the develop-
ment of vasculitis. We therefore call this system a
polygene network of vasculitis.
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